Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. - Rugo HS; Campbell M; Yau C; Jo Chien A; Wallace AM; Isaacs C; Boughey JC; Han HS; Buxton M; Clennell JL; Asare SM; Steeg K; et al. (Breast cancer research and treatment, 2025)